Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Firsekibart vs Anakinra in Adult-Onset Still's Disease
ChiCTR2500109835Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Sep 2025
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial in adult-onset Still's disease (AOSD) comparing Firsekibart arm with Anakinra arm (2 arms). Primary endpoint: Clinical inactive disease (CID) at Week 24. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
genakumabanakinra
03
Conditions
adult-onset Still's disease (AOSD)
Beyond the preview
Go deeper on ChiCTR2500109835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109835.